title: Influence of lipopolysaccharide-binding protein on pulmonary inflammation in gram-negative pneumonia.
abstract: Lipopolysaccharide-binding protein (LBP) is upregulated as part of the acute-phase response. Lipopolysaccharide-binding protein has a known multifunctional role in potentiating the recognition, clearance, and killing of gram-negative bacteria. In a Klebsiella pneumonia model, we previously demonstrated that LBP gene-deficient mice (LBP-/-) mice experience increased mortality when compared with wild-type (Wt) mice (98% vs. 59%). We hypothesize that LBP is essential to bacterial clearance from the lung, and its absence leads to alteration of the pulmonary inflammatory response to pneumonia. Twelve- to 16-week-old female C57Bl/6 Wt mice and age-matched LBP-/- mice were administered 1 × 10(3) colony-forming units of Klebsiella pneumoniae by intratracheal injection. Animals were euthanized at 6, 12, 24, or 36 h after inoculation. Lung tissue and bronchoalveolar lavage samples were obtained. Lung homogenate samples were assayed to determine quantitative bacterial load per whole lung, proinflammatory cytokine concentrations, myeloperoxidase activity, and assessment of pulmonary leukocyte populations. In vitro production of inflammatory mediators were also assayed after LPS stimulation of peritoneal macrophages isolated from Wt, Toll-like receptor 4 (TLR4)-deficient, and LBP-/- mice. The LBP-/- mice demonstrated significantly elevated levels of bacteria in the lung at 24 and 36 h when compared with Wt controls. The average lung levels of proinflammatory cytokines interleukin-1β (IL-1β), IL-6, keratinocyte-derived chemokine, and macrophage-inflammatory protein-2 were greater in the LBP mice and remained elevated longer when compared with those in the Wt mice. Myeloperoxidase activity, an indicator of neutrophil content, was significantly increased at time 36 h in the LBP mice. After in vitro stimulation of peritoneal macrophages with LPS, production of IL-1β, IL-6, IL-10, keratinocyte-derived chemokine, and macrophage-inflammatory protein-1α were suppressed in LBP and TLR4-deficient mice compared with that in Wt. Absence of a functional LBP-/- gene results in diminished clearance of gram-negative bacteria from the pulmonary system. Failure to recognize and clear gram-negative bacteria via the LBP/TLR4 axis results in an initial delayed inflammatory response. This delay in LBP-/- mice is followed by excessive amplification and prolonged elevation of proinflammatory mediators and neutrophil sequestration within the lungs.
authors: *Department of Surgery, University of Michigan Medical School, Ann Arbor, Michigan; †Center for Thrombosis and Hemostasis, University Medical Center Mainz, Mainz, Germany; and Departments of ‡Pathology and §Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan.
authors: Michael A
authors: MA
authors: Taddonio
authors: Vladislav
authors: V
authors: Dolgachev
authors: Markus
authors: M
authors: Bosmann
authors: Peter A
authors: PA
authors: Ward
authors: Grace
authors: G
authors: Su
authors: Stewart C
authors: SC
authors: Wang
authors: Mark R
authors: MR
authors: Hemmila
mesh_terms: D000209:Acute-Phase Proteins / Q000235:genetics / Q000378:metabolism*; D000818:Animals; D002352:Carrier Proteins / Q000235:genetics / Q000378:metabolism*; D054426:Chemokine CXCL2 / Q000378:metabolism; D018925:Chemokines / Q000378:metabolism; D005260:Female; D053583:Interleukin-1beta / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D008168:Lung / Q000276:immunology* / Q000378:metabolism; D017737:Macrophages, Peritoneal / Q000276:immunology / Q000378:metabolism; D008562:Membrane Glycoproteins / Q000235:genetics / Q000378:metabolism*; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D018410:Pneumonia, Bacterial / Q000235:genetics / Q000276:immunology* / Q000378:metabolism*; D051197:Toll-Like Receptor 4 / Q000235:genetics / Q000378:metabolism; D000099231:Lipopolysaccharide-Binding Protein
chemical_list: D000209:Acute-Phase Proteins; D002352:Carrier Proteins; D054426:Chemokine CXCL2; D018925:Chemokines; D053583:Interleukin-1beta; D015850:Interleukin-6; D008562:Membrane Glycoproteins; D051197:Toll-Like Receptor 4; D000099231:Lipopolysaccharide-Binding Protein; C074302:keratinocyte-derived chemokines
references: Nature. 1997 Oct 16;389(6652):742-5
references: 9338787
references: Am J Respir Crit Care Med. 1997 Mar;155(3):937-44
references: 9117029
references: J Immunol. 1999 Jun 15;162(12):7454-60
references: 10358200
references: Infect Immun. 2005 Jan;73(1):532-45
references: 15618193
references: J Trauma. 2005 Jun;58(6):1110-8; discussion 1118
references: 15995456
references: Am J Physiol Lung Cell Mol Physiol. 2005 Nov;289(5):L731-8
references: 16024722
references: J Immunol. 2006 Mar 1;176(5):3189-95
references: 16493079
references: Am J Respir Cell Mol Biol. 2009 Jul;41(1):76-84
references: 19097982
references: J Immunol. 2012 May 15;188(10):5086-93
references: 22491257
references: Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):3507-12
references: 23401516
references: Surg Clin North Am. 2014 Dec;94(6):1135-49
references: 25440115
references: Hepatology. 2000 Apr;31(4):932-6
references: 10733550
references: Am J Respir Cell Mol Biol. 2000 Aug;23(2):146-53
references: 10919979
references: J Surg Res. 2000 Dec;94(2):159-66
references: 11104656
references: J Clin Invest. 2001 Jan;107(2):225-34
references: 11160139
references: J Immunol. 2001 Sep 1;167(5):2759-65
references: 11509620
references: Shock. 2002 Sep;18(3):248-54
references: 12353926
references: Infect Immun. 2003 Dec;71(12):6747-53
references: 14638760
references: Int Immunol. 2004 Nov;16(11):1605-11
references: 15452020
references: J Exp Med. 1989 Oct 1;170(4):1231-41
references: 2477488
references: Science. 1990 Sep 21;249(4975):1431-3
references: 1698311
references: J Clin Invest. 1992 Dec;90(6):2209-19
references: 1281827
references: J Exp Med. 1994 Jan 1;179(1):269-77
references: 7505800
references: Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):7922-6
references: 7520172
references: J Exp Med. 1994 Sep 1;180(3):1025-35
references: 8064223
references: J Clin Invest. 1998 May 15;101(10):2065-71
references: 9593762